Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549235 | 0.78 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL27737645 | 0.67 | CYP19A1 (0.50) | CYP19A1KDM1AKDM4EPOLBL3MBTL1 | |
| SCHEMBL5045380 | 0.67 | KDM1A (0.42) | CYP19A1KDM1AKDM4EPOLBL3MBTL1 | |
| SCHEMBL486034 | 0.66 | ESR1 (0.36) | CYP19A1KDM1AKDM4EPOLBL3MBTL1 | |
| SCHEMBL5954664 | 0.64 | KDM1A (0.53) | CYP19A1KDM1A | |
| SCHEMBL1587906 | 0.63 | — | — | |
| SCHEMBL8856057 | 0.61 | MAPK1 (0.30) | — | |
| SCHEMBL22390150 | 0.61 | KDM1A (0.33) | KDM1A | |
| SCHEMBL21273997 | 0.61 | KDM4E (0.39) | KDM4EPOLBL3MBTL1 | |
| SCHEMBL486040 | 0.61 | TLR4 (0.35) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118820-A | Sesquiterpenoids penicipenoid E and preparation method and application thereof | 上海交通大学医学院附属仁济医院 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024117165-A1 | ADHESIVE COMPOSITION, ADHESIVE SHEET, ADHESIVE SHEET EQUIPPED WITH MOLD RELEASE FILM, LAMINATE FOR IMAGE DISPLAY DEVICES, IMAGE DISPLAY DEVICE, AND ADHESIVE SHEET FOR ORGANIC EL DISPLAY DEVICES | 三菱ケミカル株式会社 | 2024-06-06 | — | — | WO | disclosed |
| CN-118005644-A | Decahydro fluorene alkaloid, preparation method and application thereof in preparation of antibacterial drugs | 中国科学院南海海洋研究所 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023190410-A1 | COMPOUND, POLYMERIZABLE COMPOSITION, CURED PRODUCT, COLOR FILTER, PARTITION WALL AND IMAGE DISPLAY DEVICE | 三菱ケミカル株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-2539316-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-20190171099-A1 | POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT | BASF SE (DE) | 2019-06-06 | — | — | US | disclosed |
| US-10241399-B2 | Polymerizable composition comprising an oxime sulfonate as thermal curing agent | BASF SE (DE) | 2019-03-26 | — | — | US | disclosed |
| EP-2668156-B1 | POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT | BASF SE (DE) | 2018-10-31 | — | — | EP | disclosed |
| US-9631048-B2 | Sulfonium compounds, their preparation and use | BASF SE (DE) | 2017-04-25 | — | — | US | disclosed |
| US-9310677-B2 | Polymerizable composition comprising an oxime sulfonate as thermal curing agent | BASF (DE) | 2016-04-12 | — | — | US | disclosed |
| EP-1472576-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-20040072767-A1 | Glucopyranose derivatives and medicaments for preventing and/or treating HIV infection diseases comprising the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-04-15 | — | — | US | disclosed |
| US-20040002007-A1 | Oxime derivatives and the use thereof as latent acids | CIBA SPECIALTY CHEMICALS CORP. | 2004-01-01 | — | — | US | disclosed |
| WO-2003067332-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-08-14 | — | — | WO | disclosed |
| EP-1320785-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-06-25 | — | — | EP | disclosed |
| EP-1095653-A9 | GLUCOPYRANOSE DERIVATIVES AND PREVENTIVES AND/OR REMEDIES FOR HIV INFECTION CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-04-03 | — | — | EP | disclosed |
| WO-2002025376-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-03-28 | — | — | WO | disclosed |
| EP-1095653-A1 | GLUCOPYRANOSE DERIVATIVES AND PREVENTIVES AND/OR REMEDIES FOR HIV INFECTION CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-02 | — | — | EP | disclosed |
| CN-1050280-A | Information recording carrier and its used adhesive composition | MITSUI PETROCEEMICAL IND LTD (JP) | 1991-03-27 | — | — | CN | disclosed |
| EP-0112658-A2 | Extraocular device for treating the eye | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072767-A1 | Glucopyranose derivatives and medicaments for preventing and/or treating HIV infection diseases comprising the same as an active ingredient | UGGT1, SLC5A1, G6PD | CYP19A1 2322/4885KDM1A 1145/4885KDM4E 1548/4885 |
| US-10241399-B2 | Polymerizable composition comprising an oxime sulfonate as thermal curing agent | SULT1E1, COX6B1, SULT1A1 | CYP19A1 63/4885KDM1A 285/4885KDM4E 81/4885 |
| US-20190171099-A1 | POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT | SULT1E1, COX6B1, SULT1A1 | CYP19A1 63/4885KDM1A 285/4885KDM4E 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.